Significant Ownership of Redmile Group, LLC

Signature - Title
/s/ Jeremy C. Green - Managing Member
Location
Larkspur, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Redmile Group, LLC.

Follow Filing Activity

Follow Redmile Group, LLC and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Significant Ownership of Redmile Group, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FATE FATE THERAPEUTICS INC Common Stock, par value $0.001 per share 15% $21,874,894 +$344,999 18,229,078 +1.6% Redmile Group, LLC 20 Apr 2026
NRIX Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share 9.9% $165,792,867 10,696,314 Redmile Group, LLC 20 Apr 2026
ANNX Annexon, Inc. Common Stock, par value $0.001 per share 9.9% $85,778,935 15,427,866 Redmile Group, LLC 31 Dec 2025
ADCT ADC Therapeutics SA Common Shares, par value CHF 0.08 per share 9.9% $47,690,576 +$92,422 12,717,487 +0.19% Redmile Group, LLC 20 Apr 2026
RGNX REGENXBIO Inc. Common Stock, par value $0.0001 per share 9.9% $43,942,300 5,062,477 Redmile Group, LLC 30 Jun 2025
NGNE Neurogene Inc. Common Stock, $0.000001 par value 9.9% $32,077,887 +$1,594,708 1,557,179 +5.2% Redmile Group, LLC 31 Dec 2025
RAPT RAPT Therapeutics, Inc. Common Stock, $0.0001 par value per share 9.9% $14,934,463 1,765,303 Redmile Group, LLC 30 Jun 2025
RAPT RAPT Therapeutics, Inc. Common Stock, $0.0001 par value per share 9.9% $12,121,231 13,932,449 Redmile Group, LLC 31 Dec 2024
ATRA Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% $10,764,875 +$659,400 751,223 +6.5% Redmile Group, LLC 12 Nov 2025
STTK Shattuck Labs, Inc. Common Stock, par value $0.0001 per share 9.9% $5,422,231 +$617,470 6,379,095 +13% Redmile Group, LLC 25 Aug 2025
ATRA Atara Biotherapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% 950,994 Redmile Group, LLC 12 May 2026
GRTS Gritstone bio, Inc. Common Stock, $0.0001 par value per share 8.2% $131,635 13,163,457 Redmile Group, LLC 31 Dec 2024
SRRK Scholar Rock Holding Corporation Common Stock, par value $0.001 per share 7.6% $445,715,088 -$40,237,607 9,066,621 -8.3% Redmile Group, LLC 31 Mar 2026
ALXO ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share 6.8% $18,474,447 +$9,168,330 9,214,188 +99% Redmile Group, LLC 31 Mar 2026
STOK Stoke Therapeutics, Inc. Common Stock, $0.0001 par value per share 6.7% $145,952,406 -$7,423,976 4,164,120 -4.8% Redmile Group, LLC 31 Mar 2026
AgomAb Therapeutics NV Common Shares, no nominal value per share 5.6% 2,735,926 Redmile Group, LLC 31 Mar 2026
IMNM Immunome, Inc. Common Stock, $0.0001 par value per share 4.9% $119,960,738 -$3,442,010 5,558,885 -2.8% Redmile Group, LLC 31 Mar 2026
ZYME Zymeworks Inc. Common Stock, par value $0.00001 per share 4.9% $63,294,210 -$7,598,499 3,705,750 -11% Redmile Group, LLC 30 Sep 2025
ABSI Absci Corporation Common Stock, $0.0001 par value per share 4.9% $22,822,347 -$1,937,601 7,607,449 -7.8% Redmile Group, LLC 10 Apr 2026
PLRX Pliant Therapeutics, Inc. Common Stock, par value $0.0001 per share 4.8% $4,545,900 2,895,478 Redmile Group, LLC 31 Dec 2024
SLN Silence Therapeutics plc Ordinary Shares, nominal value GBP 0.05 per share 4.7% 6,644,841 -7.7% Redmile Group, LLC 31 Mar 2025
FOLD Amicus Therapeutics, Inc. Common Stock, par value $0.01 per share 4.6% $106,667,402 14,184,495 Redmile Group, LLC 31 Dec 2024
REPL Replimune Group, Inc. Common Stock, par value $0.001 per share 0.7% $2,245,077 -$18,279,751 535,818 -89% Redmile Group, LLC 30 Sep 2025
IGMS IGM Biosciences, Inc. Common Stock, par value $0.01 per share 0% $0 0 Redmile Group, LLC 14 Aug 2025

Schedules 13D/G Reported by Redmile Group, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .